Expand all sections

Veliparib

Extended indication Breast cancer; early-stage triple-negative - neoadjuvant therapy with carboplatin
Therapeutic value No judgement

Product

Active substance Veliparib
Domain Oncology and Hematology
Main indication Breast cancer
Extended indication Breast cancer; early-stage triple-negative - neoadjuvant therapy with carboplatin
Manufacturer Abbvie
Additional remarks Klinische studies zijn stopgezet in april 2017 voor deze indicatie.

Registration

There is currently nothing known about registration.

Therapeutic value

Therapeutic value No judgement
Duration of treatment Not found

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.